NeOnc Technologies Awarded $2.5M in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia in Ph 2 trials
“Securing $2.5 million in competitive NIH grants during one of the most uncertain federal funding periods reaffirms the scientific and clinical promise of NEO212,” said Dr. Thomas Chen, CEO and Chief Medical Officer of NeOnc Technologies Holdings, Inc. “As a brain and spine oncologic surgeon for over 30 years at Keck Medical Center of USC, I have witnessed the urgent need for novel, less toxic therapies. These grants are a testament to our research team’s commitment and our ability to translate academic science into meaningful treatments.”
Share:
More News
“These data underscore gotistobart’s potential to redefine treatment for patients with hard-to-treat squamous NSCLC whose disease has progressed after initial therapy and who face limited options,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “In second- and later lines of treatment, the clinical relevance of novel
“The collaboration with Ratio represents an exciting opportunity to explore the potential of novel radiopharmaceutical approaches designed to address the complexity and heterogeneity of cancer,” said Ben Hickey, President of RayzeBio. “The combination of our respective technologies and complementary development expertise creates a strong foundation for generating a novel differentiated
“We believe these results mark a potentially important step forward in the treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer,” said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. “To address the unmet medical needs of patients and their families, we will continue working closely with
“Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations,” stated Charles Morris, MBChB, MRCP, Chief Medical Officer of Prelude. “Dual KAT6A/B inhibitors, however, demonstrated overlapping toxicities with current backbone therapies that may limit the utility in earlier lines